Literature DB >> 15897562

Genetic abnormalities and patterns of antigenic expression in multiple myeloma.

Gema Mateo1, Mariana Castellanos, Ana Rasillo, Norma C Gutiérrez, Ma Angeles Montalbán, Ma Luisa Martín, Jesús Ma Hernández, Ma Consuelo López-Berges, Laura Montejano, Joan Bladé, Ma Victoria Mateos, Anna Sureda, Javier de la Rubia, Joaquín Díaz-Mediavilla, Atanasio Pandiella, Juan José Lahuerta, Alberto Orfao, Jesús F San Miguel.   

Abstract

Myelomatous plasma cells show a high heterogeneity both in their immunophenotypic characteristics as well as in their cytogenetic features. Thus far, no extensive studies have been carried out to explore whether such antigenic diversity is associated with specific genetic characteristics. We have investigated the relationship between the immunophenotypic profile at plasma cell and both their DNA ploidy status (evaluated by flow cytometry) and specific genetic features (ascertained by fluorescence in situ hybridization) in a large series of 915 patients with newly diagnosed multiple myeloma. The non-hyperdiploid multiple myeloma group (n = 454, 52%) was associated with a significantly higher frequency of positivity for CD28 and CD20 as well as a higher incidence of CD56(-) and CD117(-) cases (P < 0.001). Remarkably, 13q deletion and immunoglobulin heavy chain (IGH) gene rearrangements, which were significantly more common in non-hyperdiploid multiple myeloma, showed a strong association with CD117(-) cases. IGH translocation to 11q13 was associated with reactivity for CD20 (P < 0.001), down-regulation of CD56 (P < 0.001), and lack of expression of CD117 (P = 0.001). By contrast, IGH translocations to other chromosome partners were almost exclusively found among CD20(-) and CD117(-) cases (P < 0.001). These results suggest that genetic categories in multiple myeloma exhibit particular immunophenotypic profiles which in turn are strongly associated with the DNA ploidy status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897562     DOI: 10.1158/1078-0432.CCR-04-1489

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.

Authors:  Martin Schmidt-Hieber; Martin Pérez-Andrés; Bruno Paiva; Juan Flores-Montero; Jose J Perez; Norma C Gutierrez; Maria-Belen Vidriales; Sergio Matarraz; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

Review 3.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

4.  Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.

Authors:  Sang-Yong Shin; Seung-Tae Lee; Hee-Jin Kim; Suk Jin Kim; Kihyun Kim; Eun Suk Kang; Sun-Hee Kim
Journal:  J Clin Lab Anal       Date:  2014-10-02       Impact factor: 2.352

5.  CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

Authors:  Megan E Murray; Catherine M Gavile; Jayakumar R Nair; Chandana Koorella; Louise M Carlson; Daniela Buac; Adam Utley; Marta Chesi; P Leif Bergsagel; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

6.  CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.

Authors:  Jayakumar R Nair; Louise M Carlson; Chandana Koorella; Cheryl H Rozanski; Gerald E Byrne; P Leif Bergsagel; John P Shaughnessy; Lawrence H Boise; Asher Chanan-Khan; Kelvin P Lee
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

7.  Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.

Authors:  T Paíno; B Paiva; J M Sayagués; I Mota; T Carvalheiro; L A Corchete; I Aires-Mejía; J J Pérez; M L Sanchez; P Barcena; E M Ocio; L San-Segundo; M E Sarasquete; R García-Sanz; M-B Vidriales; A Oriol; M-T Hernández; M-A Echeveste; A Paiva; J Blade; J-J Lahuerta; A Orfao; M-V Mateos; N C Gutiérrez; J F San-Miguel
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

8.  Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+).

Authors:  Luiz Arthur Calheiros Leite; Daniela Márcia Bahia Kerbauy; Elisa Kimura; Mihoko Yamamoto
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 9.  From the bench to the bedside: emerging new treatments in multiple myeloma.

Authors:  Constantine S Mitsiades; Patrick J Hayden; Kenneth C Anderson; Paul G Richardson
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

10.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.